Remdesivir and COVID-19

I commend Yeming Wang and colleagues on their study in the difficult time of the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.

Wang and colleagues calculated a sample size of 453 patients (302 to remdesivir and 151 to placebo). However, only 237 patients were enrolled and randomly assigned (158 to remdesivir and 79 to placebo). The authors’ justification for not attaining the predetermined sample size was because at the time of the study, the COVID-19 outbreak was brought under control in China.